Helix BioPharma (TSE:HBP – Get Free Report) released its earnings results on Friday. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter, FiscalAI reports.
Helix BioPharma Price Performance
Helix BioPharma stock opened at C$0.99 on Friday. The company has a debt-to-equity ratio of 2.44, a current ratio of 0.45 and a quick ratio of 1.03. Helix BioPharma has a 1-year low of C$0.82 and a 1-year high of C$2.60. The company has a market cap of C$75.61 million, a PE ratio of -24.75 and a beta of 1.15. The stock’s 50 day moving average price is C$1.29 and its 200 day moving average price is C$1.63.
About Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The Company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA¿, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA¿, a pre-IND gemcitabine prodrug for advanced solid tumors.
Featured Articles
- Five stocks we like better than Helix BioPharma
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
